Physician profile
Christopher Oxendine
NPI 1194985234
$8,428.72
in general payments reported to CMS, 2019-2025
55 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $965 · 2021: $1,572 · 2022: $1,117 · 2023: $1,308 · 2024: $1,206 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.81 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $706.99 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $674.93 | 2019-2025 | Evenity, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $584.73 | 2019-2025 | Farxiga, Breztri |
| Lundbeck LLC | $493.25 | 2022-2025 | Vyepti, Rexulti |
| Novo Nordisk INC | $461.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $368.28 | 2019-2025 | |
| Abbott Laboratories | $308.57 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $268.35 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $257.77 | 2022-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $237.48 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Pfizer INC. | $215.18 | 2020-2025 | |
| Insulet Corporation | $183.94 | 2023 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $182.30 | 2021-2025 | Hyqvia, Trintellix |
| Dexcom, INC. | $165.13 | 2021-2025 | Dexcom G6 Transmitter |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.25 | 2020-2023 | Synjardy, Tradjenta, Jardiance |
| Allergan, INC. | $141.76 | 2020 | |
| Daiichi Sankyo INC. | $137.51 | 2021-2025 | Injectafer |
| Nestle Healthcare Nutrition INC. | $130.84 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $111.51 | 2019-2022 | |
| Eisai INC. | $110.06 | 2021-2025 | |
| Argenx US, INC. | $109.38 | 2023-2025 | Vyvgart Hytrulo |
| Sanofi-Aventis U.S. LLC | $107.09 | 2019-2023 | |
| Esperion Therapeutics, INC. | $83.21 | 2021-2025 | Nexletol |
| Ucb, INC. | $81.03 | 2025 | Rystiggo, Nayzilam, Fintepla |
| E.R. Squibb & Sons, L.L.C. | $76.87 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $74.76 | 2020-2021 | |
| Ibsa Pharma INC. | $63.11 | 2021-2024 | Tirosint, Licart, Tirosint |
| Antares Pharma, INC. | $59.63 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $58.02 | 2021-2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company LTD. | $56.51 | 2022 | |
| Mylan Specialty L.P. | $51.79 | 2020-2021 | |
| Exact Sciences Corporation | $46.62 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $46.48 | 2020-2024 | Gardasil 9, Capvaxive, Gardasil |
| Cranial Technologies, INC | $38.00 | 2023-2024 | Doc Band |
| Corcept Therapeutics | $36.93 | 2024-2025 | Korlym |
| Medtronic, INC. | $31.56 | 2021 | |
| Sumitomo Pharma America, INC. | $31.28 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $30.70 | 2023 | Austedo Xr, Ajovy |
| Endogastric Solutions, INC | $29.80 | 2020 | |
| Shire North American Group INC | $25.63 | 2019 | |
| Alkermes, INC. | $25.53 | 2023 | Vivitrol |
| Abiomed | $24.88 | 2024 | Impella |
| Alnylam Pharmaceuticals INC. | $24.10 | 2025 | Givlaari |
| Irhythm Technologies, INC. | $23.90 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.06 | 2024 | Caplyta |
| Vital Connect, INC | $21.63 | 2025 | Vitalpatch Rtm |
| Axsome Therapeutics, INC. | $20.59 | 2024 | Auvelity |
| Acadia Pharmaceuticals INC | $19.80 | 2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $19.19 | 2021 | |
| Tg Therapeutics, INC. | $18.56 | 2025 | |
| Access Pro Medical, LLC | $17.76 | 2022 | |
| Sanofi Pasteur INC. | $15.03 | 2023 | |
| C2n Diagnostics, LLC | $14.25 | 2025 | Precivityad2 |
| Hologic Sales and Service, LLC | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Oxendine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.